Department of Critical Care Medicine, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Department of Critical Care Medicine, The Center for Critical Care Nephrology, Pittsburgh, PA, USA.
Pediatr Transplant. 2020 Feb;24(1):e13608. doi: 10.1111/petr.13608. Epub 2019 Oct 25.
AKI after pediatric liver transplantation is associated with increased morbidity and mortality. The role of urinary biomarkers for the prediction of AKI in pediatric patients after liver transplantation has not been previously reported. The primary objective of this prospective pilot study was to determine the predictive capabilities of urinary KIM-1, NGAL, TIMP-2, and IGFBP7 for diagnosing AKI.
Sixteen children undergoing liver transplantation were enrolled in the study over a 19-month time period. The Kidney Disease Improving Outcomes criteria for urine output and serum creatinine were used to define AKI. Predictive ability was evaluated using the area under the curve obtained by ROC analysis.
AKI occurred in 6 (37.5%) of the patients between 2 and 4 days after transplant. There were no differences in any of the biomarkers prior to transplant. When obtained within 6 hours after transplant, the area under the ROC curve for predicting AKI was 0.758 (95% CI: 0.458-1.00) for KIM-1, 0.900 (95% CI: 0.724-1.00) for NGAL, and 0.933 (95% CI: 0.812-1.00) for the product of TIMP-2 and IGFBP7 ([TIMP-2]·[IGFBP7]).
Our results show that both NGAL and [TIMP-2]·[IGFBP7] provide significant discrimination for AKI risk following liver transplant in children. Larger studies are needed to determine the optimal time point for measuring these biomarkers and to validate our findings.
小儿肝移植后急性肾损伤(AKI)与发病率和死亡率增加有关。尿生物标志物在预测肝移植后小儿 AKI 中的作用尚未见报道。本前瞻性初步研究的主要目的是确定尿 KIM-1、NGAL、TIMP-2 和 IGFBP7 对诊断 AKI 的预测能力。
在 19 个月的时间内,有 16 名接受肝移植的儿童入组本研究。使用 KDIGO 关于尿量和血清肌酐的标准定义 AKI。使用 ROC 分析获得的曲线下面积评估预测能力。
移植后 2-4 天,6 名(37.5%)患者发生 AKI。移植前,所有生物标志物均无差异。在移植后 6 小时内获得时,KIM-1 预测 AKI 的 ROC 曲线下面积为 0.758(95%CI:0.458-1.00),NGAL 为 0.900(95%CI:0.724-1.00),TIMP-2 和 IGFBP7 的乘积([TIMP-2]·[IGFBP7])为 0.933(95%CI:0.812-1.00)。
我们的结果表明,NGAL 和[TIMP-2]·[IGFBP7]均能为儿童肝移植后 AKI 风险提供显著的区分。需要更大的研究来确定测量这些生物标志物的最佳时间点并验证我们的发现。